The pricing logic of the capital market often lies in the misalignment between financial performance figures and market sentiment. On March 27th, after "China's Smile Leader" ANGELALIGN (06699.HK) released its 2025 financial results, the secondary market provided a clear response: the stock price accumulated a gain of approximately 37.35% within one month of the report's release. The market evidently understood the signals conveyed by this annual report. Case volume, rather than revenue or net profit, is becoming the core anchor for the capital market's repricing of ANGELALIGN. However, the flip side of the rapid case volume growth is a "market share valuation game" requiring prudent assessment. The domestic average selling price (ASP) fell by 12.6% year-on-year, dragged down by centralized procurement policies and expansion into lower-tier markets. While overseas expansion is fast, it comes with implied patent litigation and compliance costs. Furthermore, the accelerated penetration into third- and fourth-tier cities and the children's early orthodontics segment are bringing hidden costs like poor doctor stability and long consumer education cycles to the forefront. As capital applauds the total case volume of 532,400, these fissures buried deep within the foundation of growth may be the key variables determining the final outcome of this valuation game.
1. ASP Trends Up Overseas, Down Domestically; Market Concentration of Leading Firms Strengthens When Lin Yue (pseudonym) started her job at age 23, she did something she had hesitated about for a long time—getting clear aligners. Crowded front teeth made her insecure in social situations, and the bulkiness of traditional "metal braces" caused the beauty-conscious young woman to delay repeatedly. Clear aligners perfectly addressed her pain points: the transparent trays were almost invisible to others and didn't interfere with eating, meetings, or dates. This is a typical profile of early Chinese clear aligner consumers: young, aesthetically driven, and hesitant about traditional orthodontics. It was millions of "Lin Yues" who supported the initial rapid growth of this track.
What is orthodontics? Simply put, it's teeth straightening. Traditional "metal braces" use metal brackets and wires to align teeth, offering good results but poor aesthetics and high discomfort. Clear aligners take a different path: doctors use intraoral scanners to obtain 3D dental data, simulate movement trajectories on a computer, and then customize a series of transparent aligners. Patients wear them sequentially according to the correction progress, gradually moving teeth into place. Made of polymer materials, the aligners are almost undetectable by others and can be removed for eating and brushing. Its essence is using digital technology to achieve customized production at the factory level, transforming a process reliant on a doctor's manual skill into treatment planning based on AI algorithms. The mainstream brands are currently the American Invisalign and China's ANGELALIGN.
China's orthodontic story is particularly compelling. China has over 1 billion patients with malocclusion, more than four times the number in the US. However, clear aligners account for only 30-40% of orthodontic cases, far from reaching the ceiling. The vast gap between supply and demand means a large pool of untapped users awaits activation. As centralized procurement policies are implemented, the industry consolidates, and players lacking core technology accelerate their exit, leading companies are entering a window of opportunity for market share concentration. ANGELALIGN's 2025 performance was delivered within this industry narrative, presenting a structurally distinct report card.
The financial report shows that in 2025, ANGELALIGN's total case volume reached 532,400, a year-on-year increase of 48.1%; total revenue was $370 million, up 37.8%; net profit was $26.3 million, surging 163%; adjusted net profit was $43.8 million, growing 63%. Meanwhile, the company's gross margin remained high in the range of 62.6% to 62.9%, and the proportion of sales and marketing expenses decreased from 39.1% to 32.8%.
However, behind the impressive performance, the rhythms of the domestic and overseas markets are starkly different. The overseas market is the absolute growth engine. In 2025, ANGELALIGN's overseas case volume was 256,200, an 82.1% increase; overseas revenue was $163 million, up 102.5%. Revenue doubled, and its growth rate outpaced case volume growth, indicating an upward trend in overseas ASP. The proportion of overseas revenue jumped from 30% to 44%, almost on par with domestic revenue. The overseas segment's adjusted loss narrowed significantly from $29.7 million to $10.5 million. The company stated in media interviews that it expects to achieve monthly breakeven in the second half of 2026.
In contrast, the domestic market presents a picture of rapid case volume growth coupled with price pressure. The financial report shows that in 2025, ANGELALIGN's domestic case volume was 276,200, a 26.3% increase, with market share continuing to expand. However, domestic revenue was only $207 million, growing 10.1%, resulting in a growth rate differential of 16 percentage points. The direct reason is a 12.6% year-on-year decline in ASP: on one side, expansion into third- and fourth-tier cities drove volume growth for mid-to-low-priced product portfolios; on the other, price reductions of 23-30% for multiple products followed their inclusion in centralized procurement.
However, the other side of the coin is that the adjusted segment profit for the Chinese mainland market reached $51.3 million, a year-on-year increase of 40.2%. Regarding the ASP difference between domestic and international markets, ANGELALIGN responded: "What everyone sees is the statistical ASP after averaging all products; we have different product portfolios in different countries, corresponding to different prices. The distribution of product structures affects the averaged ASP, which should not be directly compared as an indicator of actual pricing levels. The company offers higher discounts to high-volume doctors overseas. As more doctors use ANGELALIGN products, discounts will decrease, and ASP will further improve."
2. "Doctor Mindshare" Becomes Core Battleground; Why Does the Capital Market Value "Volume Over Price"? Within one month of the earnings release, ANGELALIGN's stock price accumulated a 37.35% gain. Brokerage research reports followed intensively, maintaining "Buy" ratings and raising target prices, with the core logic pointing to "consolidated domestic and international businesses driving sustained high case volume growth."
The signal for this round of gains is not difficult for the market to identify. When revenue growth (37.8%) lags behind case volume growth (48.1%), the capital market still gives a positive valuation, indicating the pricing logic is shifting from "how much the company sold" to "how much market share it captured in the industry." A 10-percentage-point growth differential might not look favorable in a manufacturing context, but in the clear aligner track, it precisely becomes the core anchor for valuation reassessment.
This is not the caprice of the capital market but is determined by the unique business model of clear aligners. This is a business-to-doctor model where first-mover advantage creates barriers. The delivery scenario and decision-making authority for clear aligner treatment are almost entirely in the hands of the dentist. Behind each case lies months of deep collaboration between the doctor and the brand, from initial diagnosis and treatment planning to multiple adjustments and follow-up monitoring. Once a doctor completes verification on a sufficient number of complex cases and builds clinical confidence, they are unlikely to switch suppliers easily.
Data from Sinolink Securities shows a strong correlation between the growth trends of Invisalign's case volume and its number of active doctors. As of 2023, the number of active doctors collaborating with Invisalign was 125,800. From 2015 to 2023, the compound annual growth rate of active doctors was 13%, coinciding with Invisalign's years of rapid performance growth. It's evident that the competition among leaders is essentially a battle for "doctor mindshare." Deep collaboration with dentists is the core asset of an aligner company. Even if new entrants match product technology, they would find it difficult to disrupt the usage habits of established doctors in the short term.
Although ANGELALIGN did not disclose the absolute number of collaborating doctors in its 2025 annual report, its strategy clearly targets the battle for "doctor mindshare": in the rapidly growing overseas market, the company continuously holds academic forums, actively engages with the doctor community, and builds clinical trust through professional empowerment. The 2025 financial report also attributed the 48.1% case volume growth to "continuously increasing recognition from top global orthodontists."
This indicates that ANGELALIGN's growth engine is not simply channel expansion but rather the recognition from the doctor community and the expansion of clinical capabilities. The choice of doctors is the underlying driver for case volume growth.
In the Chinese market, the implementation of industry-wide centralized procurement policies is forcing the clear aligner market into its first consolidation phase. After Shaanxi province led a procurement alliance of 15 provinces for orthodontic consumables in 2022, the price system for clear aligners was systematically lowered, compressing profit margins. The survival space for mid-to-low-tier brands lacking core technology and operational experience has drastically narrowed. In December 2025, the domestic brand Meilike, which once covered over 1800 cities nationwide and served nearly 50,000 clinics, ceased operations due to "technical and operational issues," becoming the first major brand to exit post-procurement. DTC brands like Smile Formula and vvsmile also encountered difficulties. Industry concentration towards leading players is a definitive trend.
Under the duopoly where ANGELALIGN and Invisalign together hold over 80% market share, ANGELALIGN's domestic revenue growth has also benefited to some extent from this round of industry consolidation. The "Angel Care Plan" launched by the company in 2024, through special subsidies and clinical guidance, absorbed doctors and patients affected by the policies, further consolidating brand credibility.
The capital market's pricing logic for case volume thus becomes clear: case volume growth is not only a driver of current revenue but also a leading indicator for future market share and industry position. ANGELALIGN's 2025 domestic case volume growth of 26.3% and overseas growth of 82.1% naturally became a positive signal for the capital market. Meanwhile, the company is accelerating its expansion into third- and fourth-tier cities, the children's market, and overseas territories. However, the price for such rapid expansion is also significant.
3. Land Grab: The Hidden Cost Game Behind Volume Expansion In 2015, 23-year-old Lin Yue, who had just started working, signed a clear aligner contract in Tianjin. To balance aesthetics and price, she chose ANGELALIGN for 30,000 RMB instead of Invisalign for 50,000 RMB. However, a decade later, at age 34, her treatment is still not complete. During the process, the treatment period was repeatedly extended, results fell short of expectations, and she experienced her doctor leaving the practice. After Lin Yue provided feedback to the hospital, the proposed solution was to transfer her follow-up appointments from Tianjin to Beijing. Lin Yue, now in Beijing, is still undergoing treatment and has not yet achieved the expected results. The hospital explained that clear aligners are aesthetically pleasing but have weaker force strength, hence the prolonged correction period.
Lin Yue's case is not an isolated one. On social media, several consumers have posted or shared their experiences in comments: some have worn aligners for six years with repeated treatment plan restarts; others have been in a cycle of "free restarts" within a five-year service period but have been unable to finish; some haven't even closed gaps after two and a half years. Behind these "enduring" cases, capital may be overlooking that rapid case volume growth does not equate to one successful smile after another. As more individuals experience prolonged treatment cycles and uncertain outcome expectations, hidden costs are quietly accumulating at the foundation of brand reputation and consumer trust.
For ANGELALIGN, which is rapidly expanding into lower-tier markets, children's early orthodontics, and overseas, Lin Yue's lengthy wait might be just the tip of the iceberg.
First is the issue of doctor stability and service quality in lower-tier markets. According to 2023 statistics, China has 300,000 registered dentists, corresponding to 40 dentists per 100,000 population, a figure significantly lower than the US (60) and Japan (80). This level is even lower in third- and fourth-tier cities. Coupled with varying levels of clear aligner expertise among doctors in these cities, aligner companies need to invest heavily in training and clinical support costs. But even after initial empowerment, if a doctor later leaves or switches to another brand, the前期投入 (front-end investment) could be wasted. Lin Yue's experience is a typical case of treatment disruption due to doctor attrition. The 12.6% year-on-year decline in domestic ASP is not only a result of price pressure but also reflects, to some extent, the complexity of service delivery in lower-tier markets.
In response, the company stated: "Over the past few years, ANGELALIGN has continuously increased its investment in third- and fourth-tier markets, providing more targeted services based on the actual needs of local doctors. The company continues to expand its sales and clinical medical support teams, regularly holds offline training activities for lower-tier markets, and our clinical medical support teams go deep into the field to support doctors. We have also established an integrated online and offline support service system to ensure grassroots doctors can better use our products. Simultaneously, the company is committed to helping doctors improve their case management capabilities, thereby increasing treatment predictability, shortening treatment cycles, and reducing restart rates."
Second is the pressure from the long education cycle and effect realization in children's early orthodontics. Unlike adult orthodontics, the decision-makers for children's early treatment are parents. Although children are in a peak growth period, typically resulting in shorter treatment cycles and faster visible results, factors like lack of awareness about early intervention, lower treatment compliance in children, and higher follow-up frequency cause many families to miss the optimal correction window. Data shows that in 2022, the intervention rate for children's malocclusion in China was only 0.95%, meaning extensive consumer education must start from scratch. ANGELALIGN has collaborated with Xiaohongshu (Little Red Book) to release trend reports and conducted science popularization through the "Angel KiD Star Plan." However, if these investments do not translate into visible correction results and satisfactory口碑 (word-of-mouth) several years later, they might instead lead to experience gaps like Lin Yue's "decade-long unresolved case," causing long-term damage to the brand.
The continuously rising legal and compliance costs of overseas operations are also unavoidable issues. Behind ANGELALIGN's doubled overseas business growth, hidden costs and expenses related to supply chain, legal affairs, and patent protection are likely rising in tandem. Notably, multiple patent lawsuits initiated by Invisalign in various countries since August 2025 have not yet led to significant provisions. Regarding this, ANGELALIGN responded: "Regarding patent litigation, based on assessments by external law firms and accounting firms, under IFRS accounting standards, there is currently no need to make risk provisions for the patent lawsuits. ANGELALIGN has been a continuous innovator in the clear aligner field for many years and has invested significant resources in patent compliance. The company expects its growth will not be materially affected by the litigation."
From a financial data perspective, ANGELALIGN's proportion of sales and marketing expenses has decreased from 39.1% to 32.8%, indicating improved operational efficiency. But efficiency improvement does not equate to risk elimination. For the three major growth engines of lower-tier markets, children's early orthodontics, and overseas expansion, cases like "Lin Yue's" remind us that case volume growth is only part of the answer. The other part, concerning doctor retention, treatment effectiveness, and long-term consumer satisfaction, equally determines the final outcome of this expansion.
ANGELALIGN's cumulative case volume has exceeded 2 million. But the endpoint of each case is not the moment the aligners are put on; it's the smile revealed after they are taken off. As more stories like "Lin Yue's" emerge, how long can the capital market's applause last?
Comments